{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:43Z","timestamp":1792715863793,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006070","name":"Society of Surgical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108552","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:30:14Z","timestamp":1790825414000},"page":"108552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma"],"prefix":"10.1016","volume":"11","author":[{"given":"R.","family":"Kanesvaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gruenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Yaoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.A.","family":"Mulansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.P.","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Talag-Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-L.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chansriwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Charoentum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-C.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Thiagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.A.H.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.108552_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2026.108552_bib2","series-title":"Global Cancer Observatory: Cancer Today","year":"2024"},{"key":"10.1016\/j.esmoop.2026.108552_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108552_bib4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/cancers15030665","article-title":"Clear cell renal cell carcinoma: from biology to treatment","volume":"15","author":"Kase","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108552_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clgc.2020.11.005","article-title":"Systemic therapies for the management of non-clear cell renal cell carcinoma: what works, what doesn\u2019t, and what the future holds","volume":"19","author":"Zoumpourlis","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108552_bib6","article-title":"The WHO 2022 classification of renal neoplasms (5th edition): salient updates","volume":"16","author":"Goswami","year":"2024","journal-title":"Cureus"},{"issue":"21","key":"10.1016\/j.esmoop.2026.108552_bib7","doi-asserted-by":"crossref","first-page":"9065","DOI":"10.7314\/APJCP.2014.15.21.9065","article-title":"Risk factors for renal cell carcinoma in a Japanese population","volume":"15","author":"Washio","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108552_bib8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MOU.0000000000000603","article-title":"Gender-specific risk factors for renal cell carcinoma: a systematic review","volume":"29","author":"Lughezzani","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"45","key":"10.1016\/j.esmoop.2026.108552_bib9","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2024.39.e293","article-title":"Sites of metastasis and survival in metastatic renal cell carcinoma: results from the Korean Renal Cancer Study Group database","volume":"39","author":"Lee","year":"2024","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.esmoop.2026.108552_bib10","first-page":"71","article-title":"Risk factors for renal cell cancer in a Japanese population","volume":"3","author":"Washio","year":"2009","journal-title":"Clin Med Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2026.108552_bib11","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1200\/JCO.2005.11.726","article-title":"Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study","volume":"23","author":"Oh","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108552_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"9612","key":"10.1016\/j.esmoop.2026.108552_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108552_bib14","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.juro.2013.04.130","article-title":"Risk factors for renal cell carcinoma in the VITAL study","volume":"190","author":"Macleod","year":"2013","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108552_bib15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/dc11-0132","article-title":"Type 2 diabetes and the risk of renal cell cancer in women","volume":"34","author":"Joh","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108552_bib16","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.juro.2014.06.014","article-title":"Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma","volume":"192","author":"Psutka","year":"2014","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108552_bib17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108552_bib18","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108552_bib19","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108552_bib38","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer\u2013results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108552_bib20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2013part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.esmoop.2026.108552_bib21","series-title":"Genetics of renal cell carcinoma (PDQ\u00ae): Health professional version. In: PDQ Cancer Information Summaries [Internet]; Published online May 9, 2025","year":"2002"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108552_bib23","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.21037\/tau-2025-565","article-title":"Long-term HIF-2alpha inhibition in von Hippel-Lindau disease: insights from LITESPARK-004","volume":"14","author":"Chen","year":"2025","journal-title":"Transl Androl Urol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108552_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(25)00099-3","article-title":"Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study","volume":"26","author":"Srinivasan","year":"2025","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108552_bib25","article-title":"Reducing risks of surgeries and complications in von Hippel-Lindau disease with belzutifan treatment in China","volume":"43","author":"Pan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108552_bib26","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108552_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21147\/j.issn.1000-9604.2019.01.02","article-title":"Chinese guidelines for diagnosis and treatment of renal cell carcinoma 2018 (English version)","volume":"31","year":"2019","journal-title":"Chin J Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108552_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2026.108552_bib29","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/jco.2013.31.6_suppl.350","article-title":"Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma","volume":"31","author":"Motzer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108552_bib30","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108552_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108552_bib32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"Choueiri","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108552_bib33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108552_bib34","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2340\/1651-226X.2025.43876","article-title":"Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?","volume":"64","author":"Decruyenaere","year":"2025","journal-title":"Acta Oncol"},{"key":"10.1016\/j.esmoop.2026.108552_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.annonc.2025.10.009","article-title":"A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)","volume":"37","author":"Hahn","year":"2026","journal-title":"Ann Oncol"},{"issue":"10460","key":"10.1016\/j.esmoop.2026.108552_bib36","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"issue":"10397","key":"10.1016\/j.esmoop.2026.108552_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108552_bib39","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.108552_bib40","article-title":"2595MO Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing ipilimumab plus nivolumab vs standard of care as first-line treatment","volume":"36","author":"Ahrens","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108552_bib41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108552_bib53","series-title":"TNM classification of malignant tumours","year":"2025"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108552_bib42","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.3390\/curroncol31080351","article-title":"Impact of timing of immunotherapy and cytoreductive nephrectomy in metastatic renal cell carcinoma: real-world data on survival outcomes from the CKCis Database","volume":"31","author":"Park","year":"2024","journal-title":"Curr Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108552_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0318896","article-title":"Survival benefits of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: evidence from a SEER-based retrospective cohort study","volume":"20","author":"Peng","year":"2025","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108552_bib44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2022.10.004","article-title":"Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"83","author":"Bakouny","year":"2023","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.esmoop.2026.108552_bib45","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.3390\/jcm14155543","article-title":"Revisiting cytoreductive nephrectomy in metastatic renal cell carcinoma: real-world evidence of survival benefit with first-line immunotherapy and targeted therapy regimens","volume":"14","author":"Manivasagam","year":"2025","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108552_bib46","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1470-2045(25)00343-2","article-title":"First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108552_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejca.2022.10.025","article-title":"Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: a three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)","volume":"178","author":"Sheng","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108552_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1248\/bpb.b24-00555","article-title":"Comparison of oncology drug lag in Japan and South Korea based on the interval between the U.S. approval and the local approval","volume":"48","author":"Tachibana","year":"2025","journal-title":"Biol Pharm Bull"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2026.108552_bib49","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.jfma.2024.07.030","article-title":"Reflection on 30 years of Taiwanese National Health Insurance: analysis of Taiwanese health system progress, challenges, and opportunities","volume":"123","author":"Tsuei","year":"2024","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108552_bib50","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/cts.12778","article-title":"Reimbursement lag of new drugs under Taiwan\u2019s National Health Insurance System compared with United Kingdom, Canada, Australia, Japan, and South Korea","volume":"13","author":"Shih","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108552_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf140","article-title":"Association of financial hardship and survival in working-age patients following cancer diagnosis in Taiwan","volume":"30","author":"Ciou","year":"2025","journal-title":"Oncologist"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602497X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602497X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:40:58Z","timestamp":1792712458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292602497X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S205970292602497X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108552","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108552"}}